Biotech RadarJobs updated

COMPANY

ResVerlogiX

resverlogix.com ↗

Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Coronary Artery Disease Dyslipidemia Atherosclerosis Post-Acute COVID-19 Syndrome COVID-19 Infection Fabry Disease Chronic Kidney Failure Acute Coronary Syndrome Cardiovascular Disease Type 2 Diabetes Mellitus Diabetes RVX000222

11Trials (company is sponsor)

Timeline

  1. Trial start Phase 2/Phase 3: A Study of Apabetalone in Subjects With Long -COVID source ↗
  2. Trial start 2: A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis source ↗
  3. Trial start Phase 1/Phase 2: Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease source ↗
  4. Trial start Phase 2/Phase 3: An Open-Label Study of Apabetalone in Covid Infection source ↗
  5. Trial start Phase 3: Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD source ↗
  6. Trial start Phase 2: Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia source ↗
  7. Trial start Phase 2: The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes source ↗
  8. Trial start Phase 2: ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation source ↗
  9. Trial start Phase 2: The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation source ↗
  10. Trial start Phase 2: Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease source ↗
  11. Trial start Phase 1/Phase 2: Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT06590324A Study of Apabetalone in Subjects With Long -COVIDPhase 2/Phase 3RecruitingApr 15, 2025Dec 30, 2025 (estimated)
NCT04894266An Open-Label Study of Apabetalone in Covid InfectionPhase 2/Phase 3TerminatedJan 14, 2022Jun 22, 2022 (actual)
NCT03228940Safety and Effect of Oral RVX000222 in Subjects With Fabry DiseasePhase 1/Phase 2WithdrawnNov 22, 2022Nov 22, 2022 (actual)
NCT03160430A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis2Not yet recruitingNov 22, 2024Nov 22, 2026 (estimated)
NCT01058018Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery DiseasePhase 2Completed2009-122010-06 (actual)
NCT00768274Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL CholesterolPhase 1/Phase 2Completed2008-092009-08 (actual)
NCT02586155Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CADPhase 3Completed2015-11Nov 30, 2020 (actual)
NCT01863225Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in DyslipidemiaPhase 2Terminated2013-052013-06 (actual)
NCT01728467The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetesPhase 2Completed2012-112014-03 (actual)
NCT01067820ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression EvaluationPhase 2Completed2011-092013-05 (actual)
NCT01423188The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I StimulationPhase 2Completed2011-082012-06 (actual)
Feedback